The Current Ratio as of December 2025 (TTM) for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) is 3.33

According to ImmuneOnco Biopharmaceuticals (Shanghai) Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.33. This represents a change of -26.68% compared to the average of 4.54 of the last 4 quarters.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) Historical Current Ratio (quarterly & annually)

How has 1541.HK Current Ratio performed in the past?

The mean historical Current Ratio of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. over the last ten years is 5.71. The current 3.33 Current Ratio has changed 5.73% with respect to the historical average. Over the past ten years (40 quarters), 1541.HK's Current Ratio was at its highest in in the December 2022 quarter at 12.60. The Current Ratio was at its lowest in in the June 2022 quarter at 0.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) Current Ratio by Quarter and Year

Discovering the peaks and valleys of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) Average Current Ratio

How has 1541.HK Current Ratio performed in the past?

The current Current Ratio of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) Current Ratio vs. Peers

How is 1541.HK’s Current Ratio compared to its peers?

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.’s Current Ratio is less than Antengene Corporation Limited (4.47), greater than Jiangsu Recbio Technology Co., Ltd. (0.32), greater than Clover Biopharmaceuticals, Ltd. (0.26), less than Hua Medicine (Shanghai) Ltd. (7.79), greater than Cutia Therapeutics (3.16), less than Medtide Inc. (0), greater than SinoMab BioScience Limited (0.87), less than OrbusNeich Medical Group Holdings Limited (12.21), greater than AIM Vaccine Co., Ltd. (0.73), less than HighTide Therapeutics Inc (3.44),

Build a custom stock screener for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmuneOnco Biopharmaceuticals (Shanghai) Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ImmuneOnco Biopharmaceuticals (Shanghai) Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.